Investigators conducted a quasi-experimental evaluation in the cardiology department of Sahloul University Hospital, enrolling 129 consecutive adults with documented coronary heart disease and following them for one year. Recruitment occurred over a single month in May 2022; patients were followed through August 2023. The team allocated participants to an intervention group (n = 38) that accepted a four-stage therapeutic patient education (TPE) program and to a control group (n = 91) receiving standard care. Enrollment for both groups applied the same inclusion and exclusion criteria and drew from the same clinical service during the same period to limit selection bias. The authors noted informed consent was required for inclusion in the TPE arm and that patients who declined participation were not reassigned to control.
The paper presents the design as pragmatic—intended to test the program under routine clinical conditions rather than in a randomized trial. The source did not provide granular detail on the TPE curriculum in this abstract, such as exact session length, educator background, or specific educational materials; those items are described only in the full article's supporting information, according to the investigators.
The study's primary outcome was the occurrence of major cardiovascular events within one year. The cohort showed a substantially lower event rate in the TPE arm compared with controls: investigators reported 21.1% in the intervention group versus 59.3% in the control group (p < 0.001). That difference drove the headline finding and defined the program's clinical signal in this setting.
Because the study used a quasi-experimental allocation rather than randomization, the authors framed the event-rate reduction as an association observed under real-world conditions. They reported prospective registration on the Pan African Clinical Trial Registry (PACTR202307694422939) and made the dataset available as supporting information with the article, allowing readers to examine outcome definitions and event adjudication in detail.
Secondary outcomes included measures of patient knowledge, lipid profile, glycated hemoglobin, and quality of life. Data indicated immediate gains in knowledge: knowledge of cardiovascular risk factors rose from 71.1% at baseline to 78.9% immediately after the intervention (p = 0.039), with roughly 60.5% of that improvement retained at three months. The study team observed that the TPE program translated into measurable biochemical change by three months.
Specifically, the intervention group experienced improvements in lipid parameters. Mean LDL cholesterol decreased from 2.53 ± 1.45 to 1.88 ± 1.11 mmol/L at three months (p < 0.001). Mean total cholesterol declined from 4.32 ± 1.47 to 3.75 ± 1.56 mmol/L over the same interval (p = 0.002). The control group moved in the opposite direction for lipids: mean LDL rose from 2.50 ± 1.55 to 2.90 ± 1.60 mmol/L (p = 0.001). The source reports glycated hemoglobin as a secondary outcome but did not include specific HbA1c values in the abstract; those figures are available in the full text and supporting tables.
Quality-of-life outcomes were listed among secondary endpoints; the abstract states improvements in knowledge and biological parameters but does not provide quality-of-life numerical results in the summary. Readers should consult the full article for the QoL instruments used and their scores over time.
The investigators described the TPE intervention as a structured, four-stage program delivered within the cardiology department, and they selected a quasi-experimental design to reflect routine care. The study was single-center and used consecutive recruitment, features that support feasibility assessment but limit external generalizability. The authors acknowledged these design constraints in their reporting.
Other limitations are evident from the source material. The allocation was not randomized; therefore, unmeasured confounding could contribute to observed differences in major cardiovascular events. The abstract and methods note that detailed elements of the TPE curriculum (for example, exact session content, educator qualifications, and frequency of contacts) were not summarized in the abstract. Long-term adherence beyond three months for biological endpoints and retention of knowledge at intervals beyond three months were not reported in the abstract. Finally, the sample size—129 patients overall with 38 in the intervention arm—restricts statistical power for subgroup analyses, a point the authors discuss in the full text.
The study was prospectively registered (PACTR202307694422939), the dataset accompanies the paper as supporting information, and the authors declared no specific funding or competing interests. Open questions that remain—documented by the study team—include the durability of biochemical and knowledge gains beyond three months and whether similar results would be reproducible in other centers or with randomized allocation. The source did not report regulatory milestones beyond trial registration.
Limitations and unanswered questions close the article rather than broad speculative commentary: reviewers and clinicians reading the full report should weigh the strong association between TPE participation and lower one-year event rates against the single-center, quasi-experimental design when considering implementation in other settings.